Low 2016/17 season vaccine effectiveness against hospitalised influenza A(H3N2) among elderly : awareness warranted for 2017/18 season
(2017) In Eurosurveillance 22(41).- Abstract
In a multicentre European hospital study we measured influenza vaccine effectiveness (IVE) against A(H3N2) in 2016/17. Adjusted IVE was 17% (95% confidence interval (CI): 1 to 31) overall; 25% (95% CI: 2 to 43) among 65-79-year-olds and 13% (95% CI: -15 to 30) among those ≥ 80 years. As the A(H3N2) vaccine component has not changed for 2017/18, physicians and public health experts should be aware that IVE could be low where A(H3N2) viruses predominate.
Please use this url to cite or link to this publication:
https://lup.lub.lu.se/record/0a50a0fd-8f00-4bc6-bc77-17fd8ce06b8d
- author
- contributor
- Gefenaite, Giedre LU
- author collaboration
- organization
- publishing date
- 2017-10
- type
- Contribution to journal
- publication status
- published
- subject
- keywords
- Adolescent, Adult, Aged, European Union, Female, Hospitalization/statistics & numerical data, Hospitals, Humans, Influenza A Virus, H3N2 Subtype/immunology, Influenza Vaccines/immunology, Influenza, Human/epidemiology, Male, Middle Aged, Outcome Assessment (Health Care), Seasons
- in
- Eurosurveillance
- volume
- 22
- issue
- 41
- publisher
- European Centre for Disease Prevention and Control (ECDC)
- external identifiers
-
- scopus:85031997178
- pmid:29043961
- ISSN
- 1560-7917
- DOI
- 10.2807/1560-7917.ES.2017.22.41.17-00645
- project
- Infectious diseases surveillance, vaccine effectiveness and determinants of acceptance
- language
- English
- LU publication?
- yes
- id
- 0a50a0fd-8f00-4bc6-bc77-17fd8ce06b8d
- date added to LUP
- 2019-04-23 10:10:28
- date last changed
- 2024-08-20 14:16:35
@article{0a50a0fd-8f00-4bc6-bc77-17fd8ce06b8d, abstract = {{<p>In a multicentre European hospital study we measured influenza vaccine effectiveness (IVE) against A(H3N2) in 2016/17. Adjusted IVE was 17% (95% confidence interval (CI): 1 to 31) overall; 25% (95% CI: 2 to 43) among 65-79-year-olds and 13% (95% CI: -15 to 30) among those ≥ 80 years. As the A(H3N2) vaccine component has not changed for 2017/18, physicians and public health experts should be aware that IVE could be low where A(H3N2) viruses predominate.</p>}}, author = {{Rondy, Marc and Gherasim, Alin and Casado, Itziar and Launay, Odile and Rizzo, Caterina and Pitigoi, Daniela and Mickiene, Aukse and Marbus, Sierk D and Machado, Ausenda and Syrjänen, Ritva K and Pem-Novose, Iva and Horváth, Judith Krisztina and Larrauri, Amparo and Castilla, Jesús and Vanhems, Philippe and Alfonsi, Valeria and Ivanciuc, Alina E and Kuliese, Monika and van Gageldonk-Lafeber, Rianne and Gomez, Veronica and Ikonen, Niina and Lovric, Zvjezdana and Ferenczi, Annamária and Moren, Alain}}, issn = {{1560-7917}}, keywords = {{Adolescent; Adult; Aged; European Union; Female; Hospitalization/statistics & numerical data; Hospitals; Humans; Influenza A Virus, H3N2 Subtype/immunology; Influenza Vaccines/immunology; Influenza, Human/epidemiology; Male; Middle Aged; Outcome Assessment (Health Care); Seasons}}, language = {{eng}}, number = {{41}}, publisher = {{European Centre for Disease Prevention and Control (ECDC)}}, series = {{Eurosurveillance}}, title = {{Low 2016/17 season vaccine effectiveness against hospitalised influenza A(H3N2) among elderly : awareness warranted for 2017/18 season}}, url = {{http://dx.doi.org/10.2807/1560-7917.ES.2017.22.41.17-00645}}, doi = {{10.2807/1560-7917.ES.2017.22.41.17-00645}}, volume = {{22}}, year = {{2017}}, }